Table 1 Baseline patient demographics and tumor characteristics. SD, standard deviation; IDC, intraductal carcinoma; ILC, intralobular carcinoma; ER, estrogen receptor; PR, progesterone receptor; Her 2, human epidermal growth factor receptor 2
Patient and Tumor Characteristics | All N = 1705 | Jewish N = 1514 | Bedouin N = 191 | p value |
|---|---|---|---|---|
Age, yrs, mean (SD) | 59.5 (14.6) | 60.8 (14.3) | 49.6 (13.8) | < 0.001 |
Tumor type, n (%) | Â | Â | Â | 0.26 |
IDC ILC Others | 1489 (87.3%) 149 (8.8%) 67 (3.9%) | 1322 (87.3%) 136 (9%) 56 (3.7%) | 167 (87.4%) 13 (6.8%) 11 (5.8%) | Â |
ER positive, n (%) | 1375 (80.6%) | 1221 (80.6%) | 154 (80.6%) | 1 |
PR positive, n (%) | 1205 (70.7%) | 1058 (69.9%) | 147 (77%) | 0.04 |
HER 2 positive, n (%) | 367 (21.5%) | 317 (20.9%) | 50 (26.2%) | 0.11 |
Triple Negative | 175 (10.3%) | 161 (10.6%) | 14 (7.3%) | 0.17 |
Tumor Stage, n (%) | Â | Â | Â | 0.02 |
T1 T2 T3 T4 | 865 (52.3%) 486 (29.4%) 74 (4.5%) 228 (13.8%) | 769 (52%) 433 (30%) 72 (6%) 193 (12%) | 96 (51%) 53 (29%) 2 (1%) 35 (19%) | Â |
Tumor Size (cm) | 2.17 (1.51) | 2.13 (1.49) | 2.50 (1.60) | < 0.001 |
Nodal Stage, n (%) | Â | Â | Â | 0.035 |
0 1 2 3 | 921 (57.8%) 503 (31.6%) 121 (7.6%) 49 (3.1%) | 836 (60%) 435 (30.7%) 105 (7.4%) 41 (2.9%) | 85 (48%) 68 (38.4%) 16 (9%) 8 (4.5%) | Â |
Metastasis | 229 (13.4%) | 193 (12.7%) | 36 (18.8%) | 0.03 |